Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer

Prostate

Volumn 39, Issue 3, 1999, Pages 175-181

  Mikkola, Arto K K ^a   Aro, Jussi L V ^b   Rannikko, S A Sakari ^a   Salo, Jaakko O ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Maria Hospital   (Finland)

Author keywords

Body mass index; Erythrocyte sedimentation rate; General condition; Hemoglobin concentration; Performance status; Sex steroid hormones

Indexed keywords

ALKALINE PHOSPHATASE; ESTRADIOL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; ESTRADIOL BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; BODY MASS INDEX; ESTRADIOL; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0033135574     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990515)39:3<175::AID-PROS5>3.0.CO;2-E     Document Type: Article

References (54)

1. Pasqualini JR. Hormonal regulation of the prostatic gland: physiology and pathology. Triangle 1982;21:21-26.
2. Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate 1996;28:17-23.
3. Andersson SO, Adami HO, Bergstrom R, Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population-based case-control study. Br J Cancer 1993;68:97-102.
4. British Prostate Study Group. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. Br J Urol 1979;51:382-389.
5. Hoisaeter PA, Haukaas S, Bakke A, Hoiem L, Segadal E, Thorsen T. Blood hormone levels related to stages and grades of prostatic cancer. Prostate 1982;3:375-381.
6. Bishop MC, Selby C, Taylor M. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine. Br J Urol 1985;57:542-547.
7. Eriksson A, Carlstrom K. Prognostic value of serum hormone concentrations in prostatic cancer. Prostate 1988;13:249-256.
8. Haapiainen R, Rannikko S, Adlercreutz H, Alfthan O. Correlation of pretreatment plasma levels of estradiol and sex-hormone-binding globulin-binding capacity with clinical stage and survival of patients with prostatic cancer. Prostate 1986;8: 127-137.
9. Haapiainen R, Rannikko S, Alfthan O, Adlercreutz H. Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Prostate 1988;12:325-332.
10. Carlstrom K, Stege R. Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls. Br J Urol 1997;79:427-431.
11. Pirke KM, Doerr P. Age related changes and interrelationship between plasma testosterone, oestradiol and testosterone-binding globulin in normal adult males. Acta Endocrinol (Copenh) 1973;74:792-800.
12. Bartsch W, Horst HJ, Becker H, Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh) 1977;85:650-664.
13. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990; 71:929-931.
14. Kley HK, Deselaers T, Peerenboom H, Kruskemper HL. Enhanced conversion of androstenedione to estrogens in obese males. J Clin Endocrinol Metab 1980;51:1128-1132.
15. Zumoff B. Relationship of obesity to blood estrogens. Cancer Res [Suppl] 1982;42:3289-3294.
16. de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol 1989;141:883-888.
17. Fossa SD, Dearnaley DP, Law M, Gad J, Newling DW, Tveter K. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 1992;3:361-366.
18. Dacie JU, Lewis SM. Practical haematology, 8th ed. Hong Kong: Churchill Livingstone; 1995. p 12-14.
19. World Health Organization. International histological classification of tumours: no. 22. Histological typing of prostate tumours. Geneva: World Health Organization; 1980. p 17-23.
20. UICC TNM-classification of malignant tumours, 3rd ed. Geneva. 1978. Enlarged and revised, 1982.
21. Rannikko S, Kairento AL, Karonen SL, Adlercreutz H. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. Acta Endocrinol (Copenh) 1981;98:625-633.
22. Adlercreutz H, Fotsis T, Heikkinen R. Current state of the art in the analysis of estrogens. In: Görög S, editor. Advances in Steroid Analysis. Budapest: Akademiai' Kiado; 1982. p 3-33.
23. Kuoppasalmi K. Plasma testosterone and sex hormone-binding globulin in physical exercise. Scand J Clin Lab Invest 1980;40: 411-418.
24. Anderson DC, Thorner MO, Fisher RA, Woodham JP, Goble HL, Besser CM. Effects of hormonal treatment on plasma unbound androgen levels in hirsute women. Acta Endocrinol (Copenh) [Suppl] 1975;80:199-224.
25. Moore JW, Clark GM, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 1982;29:17-21.
26. Goldbourt U, Medalie JH. Weight-height incides. Choice of the most suitable index and its association with selected variables among 10,000 adult males of heterogenous origin. Br J Prev Soc Med 1974;28:116-126.
27. Rainwater LM, Morgan WR, Klee GG, Zincke H. Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc 1990;65:1118-1126.
28. Imai K, Tomaru Y, Ohnuki T, Yamanaka H, Sakai H, Kanetake H, Minami Y, Nomata K, Saito Y. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis. Cancer 1992;69: 2983-2989.
29. Weinstein RL, Kelch RP, Jenner MR, Kaplan SL, Grumbach MM. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 1974;53:1-6.
30. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979;49:905-916.
31. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
32. Caprio M, Aversa A, Giannini D, Fabbrini E, De Martino M, Marini M, Spera G, Fabbri A. Testosterone decrease in obese men: role of leptin. Int J Androl [Suppl] 1998;21:28.
33. Jockenhovel F, Blum WF, Vogel E, Englaro P, Muller-Wieland D, Reinwein D, Rascher W, Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997;82:2510-2513.
34. Elbers JM, Asscheman H, Seidell JC, Frolich M, Meinders AE, Gooren LJ. Reversal of sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 1997;82:3267-3270.
35. Palmert MR, Radovick S, Boepple PA. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty. J Clin Endocrinol Metab 1998;83:1091-1096.
36. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991;265:618-621.
37. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer [Suppl] 1993;72:3788-3792.
38. Imai K, Suzuki T, Kobayashi M, Yamanaka H, Tomaru Y, Sato J. The significance of erythrocyte sedimentation rate as a prognostic factor for patients with prostate cancer: Gunma Urological Oncology Study Group investigation. Jpn J Cancer Res 1990;81: 971-974.
39. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988;48:3515-3517.
40. Barret-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-173.
41. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
42. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
43. Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 1997;6:967-969.
44. Rannikko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983;4:223-229.
45. Rannikko S, Adlercreutz H, Haapiainen R. Urinary oestrogen excretion in benign prostatic hyperplasia and prostatic cancer. Br J Urol 1989;64:172-175.
46. Daniell HW. A better prognosis for obese men with prostate cancer. J Urol 1996;155:220-225.
47. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farrugio R, Oliveri G, Calabro M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995;136:2309-2319.
48. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Lo Casto M, Vidali G, Castagnetta L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994;54:1190-1193.
49. Yatani R, Chigusa I, Akazaki K, Stemmerman GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982;29:611-616.
50. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342: 1209-1210.
51. Setchell KDR, Adlercreuz H. Mammalian lignans and phyto-oestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In: Rowland I, editor. Role of the gut flora in toxicity and cancer. London: Academic Press; 1988. p 315-345.
52. Price KR, Fenwick GR. Naturally occurring oestrogens in food - a review. Food Addit Contam 1985;2:73-106.
53. Shutt DA, Cox RI. Steroid and phyto-estrogen binding to sheep uterine receptors in vitro. J Endocrinol 1972;52:299-310.
54. Shibata A, Whittemore AS. Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate 1997;32:65-72.